Gosset Ownership
Private
Employees
~7
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Radar Therapeutics General Information
Radar Therapeutics is developing a new class of smart, programmable mRNA medicines that use proprietary RNA sensors. These therapies are designed for in vivo targeting—therapeutic proteins or other payloads are only expressed in cells with specific disease-associated transcriptomic signatures. This approach aims to maximize efficacy while minimizing off-target toxicity. As of mid-2024, all programs remain preclinical; no clinical results have been reported yet.
Contact Information
Primary Industry
Biotech
Corporate Office
Berkeley, California
USA
USA
Drug Pipeline
No pipeline data available
Key Partnerships
No major pharmaceutical partnerships announced yet; investors include Eli Lilly & Co., NfX Bio, Biovision Ventures, KdT Ventures, PearVC, BEVC.
Radar Therapeutics Funding
No funding data available
To view Radar Therapeutics's complete valuation and funding history, request access »